B large-cell lymphoma in children and adolescents

Cancer Treatment Reviews

Volumn 29, Issue 2, 2003, Pages 91-98

  Raetz, Elizabeth ^a   Perkins, Sherrie ^b   Davenport, Virginia ^c   Cairo, Mitchell S ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adolescent; Antibody; Burkitt's; Burkitt like; Chemotherapy; Childhood; Large cell; Survival

Indexed keywords

ALLOPURINOL; CD20 ANTIGEN; CD22 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RASBURICASE; RITUXIMAB; URATE OXIDASE; VINCRISTINE;

ADOLESCENT; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CYTOGENETICS; DIURESIS; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HUMAN; HYDRATION; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 0037398184     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00108-1     Document Type: Review

References (56)

1. Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL. Lymphomas and reticuloendothelial neoplasms. In: Ries LAG, Smith MA, Gurney JG et al., (eds.), Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute: Bethesda, MD, 1999; 35-50.
2. Perkins SL, Segal GH, Kjeldsberg CR. Classification of non-Hodgkin's lymphomas in children. Semin Diagn Pathol 1995; 12: 303-313.
3. Purtilo DT, Strobach RS, Okano M, Davis JR. Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 1992; 67: 5-23.
4. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992; 80: 8-20.
5. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992; 52: 5465s-5467s.
6. Rappaport H. In: Tumours of the haematopoietic system Atlas of Tumour Pathology. Armed Forces Institute of Pathology: Washington, DC, 1966; 10-14.
7. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34(Suppl): 1488-1503.
8. Lennert K, Feller A. Histopathology of Non-Hodgkin's Lymphoma. Springer-Verlag: New York, 1992.
9. The non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute-sponsored study of classifiaciton of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
10. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 4: 1361-1392.
11. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Haematol Oncol 2001; 19: 129-150.
12. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 1238-1248.
13. Cairo MS. Current advances and future strategies in B-large cell lymohoma in children and adolescents. Proc Am Soc Clin Oncol 2002: 512-519.
14. Perkins SL. Work-up and diagnosis of paediatric non-Hodgkin's lymphomas. Pediatr Dev Pathol 2000; 3: 374-390.
15. Lones MA, Perkins SL, Sposto R, Kadin ME, Kjeldsberg CR, Wilson JF, Cairo MS. Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol 2000; 18: 3845-3853.
16. Lones MA, Cairo MS, Perkins SL. T-cell-rich large B-cell lymphoma in children and adolescents: a clinicopathologic report of six cases from the Children's Cancer Group Study CCG-5961. Cancer 2000; 88: 2378-2386.
17. Chu PG, Chang KL, Arber DA, Weiss LM. Practical applications of immunohistochemistry in haematolymphoid neoplasms. Ann Diagn Pathol 1999; 3: 104-133.
18. Perkins SL, Lones MA, Davenport G, Cairo MS. B-cell lymphoma/leukaemia (BCLL) in children and adolescents: central phenotype results from Children's Cancer Group Study (CCG)-5961 and implications for future targeted bio-immune therapy (TBIT). Med Pediatr Oncol 2001; 37: 172 (abstract).
19. Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, Delsol G, Mason DY. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol 2000; 109: 584-591.
20. Segal GH, Kjeldsberg CR, Smith GP, Perkins SL. CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am J Clin Pathol 1994; 102: 292-298.
21. Barth TF, Leithauser F, Moller P. Mediastinal B-cell lymphoma, a lymphoma type with several characteristics unique among diffuse large B-cell lymphomas. Ann Haematol 2001; 80(Suppl 3): B49-B53.
22. Staudt LM, Dent AL, Shaffer AL, Yu X. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6. Int Rev Immunol 1999; 18: 381-403.
23. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani R, Levy R. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-951.
24. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90: 1168-1174.
25. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
26. Goldsby RE, Carroll WL. The molecular biology of paediatric lymphomas. J Pediatr Haematol/Oncol 1998; 20: 282-296.
27. Chang CC, Liu YC, Cleveland RP, Perkins SLO. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 2000; 113: 512-518.
28. Le Beau MM, Rowley JD. Chromosomal abnormalities in leukaemia and lymphoma: clinical and biological significance. Adv Hum Genet 1986; 15: 1-54.
29. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
30. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukaemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99: 409-426.
31. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
32. Sandlund JT, Murphy SB, Santana VM, Behm F, Jones D, Berard CW, Furman WL, Ribeiro R, Crist WM, Greenwald C, Chen G, Walter A, Pui CH. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3018-3024.
33. Murphy SB. Paediatric lymphomas: recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 1994; 5(Suppl 1): 31-33.
34. Cairo M, Gerrard M, Patte C. A new protocol for treatment of mature B-cell lymphoma/leukaemia (BCLL): FAB LMB 96, a SFOP LMB 96/CCG-5961/UKCCSG NHL 9600 international cooperative study. Med Pediatr Oncol 1997; 29: 320a (abstract).
35. Magrath I. Malignant Non-Hodgkin's Lymphomas in Children. Lippincott-Raven Publishers: Philadelphia, 2001.
36. Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990; 322: 1169-1174.
37. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukaemia at high risk for tumour lysis. Blood 2001; 97: 2998-3003.
38. Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, Ribeiro RC, Sandlund JT, Rivera GK, Evans WE, Mahmoud HH. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukaemia 1997; 11: 1813-1816.
39. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukaemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
40. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in paediatric and adult patients: results of a compassionate-use trial. Leukaemia 2001; 15: 1505-1509.
41. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphael M, Terrier-Lacombe MJ. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumour burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukaemia. Blood 2001; 97: 3370-3379.
42. Meadows AT, Sposto R, Jenkin RD, Kersey JH, Chilcote RR, Siegel SE, Coccia PF, Rosenstock J, Pringle KC, Stolar CJ, Kadin M, Hammond G. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7: 92-99.
43. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337: 1259-1266.
44. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Muller-Weihrich S, Pluss HJ, Zintl F, Henze G, Riehm H. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
45. Patte C, Philip T, Rodary C, Zucker JM, Behrendt H, Gentet JC, Lamagnere JP, Otten J, Dufillot D, Pein F, Caillou B, Lemerle J. High survival rate in advanced-stage B-cell lymphomas and leukaemias without CNS involvement with a short intensive polychemotherapy: results from the French Paediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991; 9: 123-132.
46. Weinstein HJ, Lack EE, Cassady JR. APO therapy for malignant lymphoma of large cell "histiocytic" type of childhood: analysis of treatment results for 29 patients. Blood 1984; 64: 422-426.
47. Hvizdala EV, Berard C, Callihan T, Falletta J, Sabio H, Shuster JJ, Sullivan M, Wharam MD. Nonlymphoblastic lymphoma in children-histology and stage-related response to therapy: a Paediatric Oncology Group study. J Clin Oncol 1991; 9: 1189-1195.
48. Laver JH, Weinstein HJ, Hutchison RE, Kepner J, Schwenn M, Tarbell N, Desai S, Murphy SB. Lineage-specific differences in outcome for advanced stage large cell lymphoma in children and adolescents: results of a randomized phase III Paediatric Oncology Group Trial. Blood 2001; 87: 345a (abstract).
49. Cairo MS, Krailo MD, Morse M, Hutchinson RJ, Harris RE, Kjeldsberg CR, Kadin ME, Radel E, Steinherz LJ, Morris E, Finlay JL, Meadows AT. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a Children's Cancer Group report. Leukaemia 2002; 16: 594-600.
50. Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, Krailo MD, Termuhlen AM, Morse M, Siegel SE. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol 2001; 37: 432-441.
51. Kobrinsky NL, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, Meadows AT. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19: 2390-2396.
52. Haddy TB, Adde MA, McCalla J, Domanski MJ, Datiles III M, Meehan SC, Pikus A, Shad AT, Valdez I, Lopez Vivino L, Magrath IT. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 1998; 16: 2070-2079.
53. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
54. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti GE, Moore DT, Hudson Jr JR, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999; 64: 71-78.
55. Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med 2002; 53: 303-318.
56. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R. Gene expression profiling of B cell chronic lymphocytic leukaemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625-1638.